Trisalus Life Sciences Inc (TLSI)
$9.68
Insights on Trisalus Life Sciences Inc
Increasing Revenue
Revenue is up for the last 5 quarters, 2.98M → 6.45M (in $), with an average increase of 16.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -35.50M → -13.21M (in $), with an average increase of 168.6% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 41.0% return, outperforming this stock by 44.4%
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 79.7% return, outperforming this stock by 78.5%
Performance
- $9.61$9.95$9.68
0.72%
Downside
Day's Volatility :3.42%
Upside
2.71%
- $3.32$16.24$9.68
65.7%
Downside
52 Weeks Volatility :79.56%
Upside
40.39%
Returns
| Period | Trisalus Life Sciences Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 6.63% | 0.0% |
6 Months | 172.4% | 0.0% |
1 Year | -3.67% | 0.0% |
3 Years | 1.01% | -20.1% |
Highlights
Market Capitalization | 275.7M |
Book Value | - $0.98 |
Earnings Per Share (EPS) | -6.73 |
Wall Street Target Price | 16.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -322.41% |
Return On Assets TTM | -141.84% |
Return On Equity TTM | -496.21% |
Revenue TTM | 18.5M |
Revenue Per Share TTM | 1.97 |
Quarterly Revenue Growth YOY | 77.3% |
Gross Profit TTM | 0.0 |
EBITDA | -53.4M |
Diluted Eps TTM | -6.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.0 |
EPS Estimate Next Year | -1.5 |
EPS Estimate Current Quarter | -0.65 |
EPS Estimate Next Quarter | -0.54 |
Analyst Recommendation
Analyst Forecast
What analysts predicted
Upside of 65.29%
Technicals Summary
Sell
Neutral
Buy
Trisalus Life Sciences Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Trisalus Life Sciences Inc | 1.32% | 172.4% | -3.67% | 1.01% | -5.23% |
 Stryker Corporation | 0.86% | 12.4% | 15.49% | 28.53% | 77.74% |
 Boston Scientific Corp. | 11.25% | 36.51% | 40.96% | 76.8% | 100.56% |
 Edwards Lifesciences Corp. | 3.89% | 34.72% | 1.32% | -5.35% | 56.97% |
 Abbott Laboratories | -3.84% | 0.25% | -4.89% | -12.22% | 35.01% |
 Medtronic Plc | 5.71% | 8.68% | -4.84% | -33.51% | -4.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Trisalus Life Sciences Inc | NA | NA | NA | -2.0 | -4.96 | -1.42 | NA | -0.98 |
Stryker Corporation | 37.6 | 37.6 | 2.92 | 11.96 | 0.19 | 0.07 | 0.01 | 50.33 |
Boston Scientific Corp. | 63.33 | 63.33 | 1.8 | 2.33 | 0.09 | 0.05 | NA | 13.56 |
Edwards Lifesciences Corp. | 38.77 | 38.77 | 5.19 | 2.76 | 0.21 | 0.12 | NA | 11.82 |
Abbott Laboratories | 32.15 | 32.15 | 5.99 | 4.63 | 0.15 | 0.06 | 0.02 | 22.31 |
Medtronic Plc | 26.83 | 26.83 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Trisalus Life Sciences Inc | NA | $275.7M | -5.23% | NA | 0.0% |
Stryker Corporation | Buy | $125.6B | 77.74% | 37.6 | 16.03% |
Boston Scientific Corp. | Buy | $110.8B | 100.56% | 63.33 | 12.05% |
Edwards Lifesciences Corp. | Buy | $54.4B | 56.97% | 38.77 | 23.01% |
Abbott Laboratories | Buy | $179.5B | 35.01% | 32.15 | 13.96% |
Medtronic Plc | Buy | $112.2B | -4.04% | 26.83 | 13.0% |
Company Information
Organization | Trisalus Life Sciences Inc |
Employees | 112 |
CEO | Ms. Mary T. Szela B.S.N., M.B.A. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$9.68
-2.91%
Keyarch Acquisition Corp
$9.68
-2.91%
Connexa Sports Technologies Inc
$9.68
-2.91%
Us Value Etf
$9.68
-2.91%
First Wave Biopharma Inc
$9.68
-2.91%
Global X Msci Next Emerging
$9.68
-2.91%
Fat Projects Acquisition Corp
$9.68
-2.91%
Ishares Intl Div Growth Etf
$9.68
-2.91%
Corsair Gaming, Inc.
$9.68
-2.91%